Trends and Finance: Page 4

Lab fraud repeat offender sentenced in $234M Medicare case

By LabPulse.com staff writers

A clinical laboratory owner, operator, and manager was ordered to forfeit nearly $32 million, surrender his personal and business property in California, and serve 10 years in prison for his roles in clinical laboratory fraud.

January 31, 2024

Jury awards Natera $96.3M in patent infringement case against CareDX

By LabPulse.com staff writers

A jury in the U.S. District Court for the District of Delaware has ruled in favor of Natera in its patent infringement case against CareDx, awarding the firm approximately $96.3 million in damages in a unanimous verdict.

January 29, 2024

BD, Techcyte team for AI-enabled digital cervical cytology system

By LabPulse.com staff writers

Becton Dickinson (BD) and Techcyte have announced a strategic collaboration agreement designed to, in time, add artificial intelligence (AI) to cervical cancer screening in the U.S.

January 30, 2024

Concentric by Ginkgo, Illumina to collaborate on biosurveillance technology

By Matt Limb

Illumina and biosecurity firm Concentric by Ginkgo have pledged to expand biosecurity capabilities to help countries “modernize defenses" against emerging biological threats.

January 24, 2024

Invitae sells reproductive health assets to Natera

By LabPulse.com staff writers

Invitae on Monday has completed the sale of some of its reproductive health assets, including carrier screening and noninvasive prenatal screening, to Natera.

January 22, 2024

Accent Therapeutics raises $75M in series C funding round

By LabPulse.com staff writers

Biopharmaceutical company Accent Therapeutics has raised $75 million in a series C financing round, with the aim of using the funds to advance two of its precision oncology candidates to clinical trials.

January 23, 2024

Ravgen wins $57M in patent infringement suit against Natera

By LabPulse.com staff writers

A jury in Austin, TX, awarded biotech firm Ravgen $57 million in damages in its patent infringement lawsuit against Natera.

January 18, 2024

Elizabeth Holmes gets 90 years exclusion

By LabPulse.com staff writers

HHS-OIG adds extended federal healthcare program exclusion onto Theranos executive's punishment.

January 19, 2024

Optithera, ELNA Medical Group, Génome Québec partner on diabetes complications risk assessment test

By LabPulse.com staff writers

Optithera, ELNA Medical Group, and Génome Québec have signed an agreement to further develop and distribute a genomic test to predict the risk of complications in patients with type 2 diabetes.

January 18, 2024

Genevant Sciences forges $114M deal with Tome Biosciences on liver disease gene therapy

By LabPulse.com staff writers

Biotech firm Genevant Sciences will collaborate with biotech startup Tome Biosciences on an in vivo gene editing treatment for a rare liver disorder.

January 16, 2024

Geneoscopy requests review of Exact Sciences patent, dismissal of lawsuit

By LabPulse.com staff writers

In the latest development in the patent infringement dispute between the two companies, Geneoscopy has petitioned the U.S. Patent and Trademark Office for inter partes review, challenging the patent in contention held by Exact Sciences.

January 12, 2024

Myrobalan Therapeutics completes $24M series A financing round

By LabPulse.com staff writers

Biotech company Myrobalan Therapeutics completed a $24 million series A financing round Wednesday.

January 11, 2024

Previous Page

Page 4 of 132

Next Page